resveratrol has been researched along with Lymphangiomyomatosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cole, AG; Gupta, N; Holz, MK; Ingledue, R; Kopras, EJ; McCormack, FX; McMahan, S; Robbins, N; Singla, A; Swigris, J; Zhang, B; Zhou, Y | 1 |
| Alayev, A; Berger, SM; Holz, MK; Snyder, RB; Sun, Y; Yu, JJ | 1 |
| Alayev, A; Holz, MK; Li, C; Salamon, RS; Schwartz, NS; Sun, Y; Yu, JJ | 1 |
3 other study(ies) available for resveratrol and Lymphangiomyomatosis
| Article | Year |
|---|---|
Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
Topics: Forced Expiratory Volume; Humans; Lymphangioleiomyomatosis; Middle Aged; Quality of Life; Resveratrol; Sirolimus; Vascular Endothelial Growth Factor D | 2023 |
Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cells, Cultured; Drug Synergism; Humans; Lymphangioleiomyomatosis; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Proto-Oncogene Proteins c-akt; Resveratrol; Signal Transduction; Sirolimus; Stilbenes; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2014 |
Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphangioleiomyomatosis; Mechanistic Target of Rapamycin Complex 1; Mice, SCID; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Resveratrol; Signal Transduction; Sirolimus; Stilbenes; TOR Serine-Threonine Kinases; Treatment Outcome; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2015 |